With $22M from BARDA, Vaxxas plans clinical trials of needle-free vaccination approach for diseases starting with flu and possibly, COVID-19
With $22 million from the Biomedical Advanced Research and Development Authority (BARDA), Vaxxas plans to advance clinical development of its proprietary High Density Micro-Array Patch (HD-MAP) non-invasive vaccination platform in response to pandemic threats to public health. [Vaxxas]
The contract from BARDA (75A50120C00180) will fund an upcoming Phase I clinical validation study designed to evaluate HD-MAP for pandemic influenza in 420 people, using both unadjuvanted and adjuvanted vaccine formulations. However, Vaxxas is also actively investigating opportunities to apply HD-MAP toward improving the performance of vaccines for other pandemics—including against COVID-19 . . .
